Skip to main content

Research Repository

Advanced Search

Tumour treating fields in a combinational therapeutic approach

Branter, Joshua; Basu, Surajit; Smith, Stuart

Tumour treating fields in a combinational therapeutic approach Thumbnail


Joshua Branter

Surajit Basu

Clinical Associate Professor


© Branter et al. The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has remained unchanged since 2005, with patients undergoing maximal surgical resection, followed by radiotherapy plus concomitant and maintenance Temozolomide. More recently, Tumour treating fields (TTFields) therapy has become FDA approved for adult recurrent and adult newly-diagnosed GBM following the EF-11 and EF-14 trials, respectively. TTFields is a non-invasive anticancer treatment which utilizes medium frequency alternating electric fields to target actively dividing cancerous cells. TTFields selectively targets cells within mitosis through interacting with key mitotic proteins to cause mitotic arrest and cell death. TTFields therapy presents itself as a candidate for the combinational therapy route due to the lack of overlapping toxicities associated with electric fields. Here we review current literature pertaining to TTFields in combination with alkylating agents, radiation, anti-angiogenics, mitotic inhibitors, immunotherapies, and also with novel agents. This review highlights the observed synergistic and additive effects of combining TTFields with various other therapies, as well highlighting the strategies relating to combinations with electric fields.

Journal Article Type Article
Acceptance Date Oct 24, 2018
Online Publication Date Nov 7, 2018
Publication Date Nov 27, 2018
Deposit Date Jan 8, 2019
Publicly Available Date Jan 8, 2019
Journal Oncotarget
Electronic ISSN 1949-2553
Publisher Impact Journals
Peer Reviewed Peer Reviewed
Volume 9
Issue 93
Pages 36631-36644
Keywords Oncology
Public URL
Publisher URL[]=26344&path[]=82054


You might also like

Downloadable Citations